Stockwatch: Biogen's belligerent repetition
This article was originally published in Scrip
Two iconic artists are brought together in unlikely combination at an exhibition that opens in Oxford this week. The patterns of William Morris's curtains and wallpapers have a sublime connection with Andy Warhol's prints of Marilyn Monroe – repetition. The theme of repetition also struck me in the most impactful clinical data release of last week.
You may also be interested in...
Rigel and Biogen both released data last week that prompted over-reactions and sensationalism, respectively from analysts, the print media and even the BBC. When something sounds too good to be true, is probably is.
As generalist investors continue to push higher the stock prices of biotech companies that announce the most tenuous of coronavirus developments, the track record of biotech companies developing even vaccines for which the antigen is proven to be safe and efficacious remains poor.
Following Mylan’s first-quarter 2020 earnings announcement, all the biggest generic pharmaceutical companies have now reported. Concerns about supply chain disruptions in March have proven to have been overblown and guidance has largely been reaffirmed. So, are generics immune from coronavirus?